Psychological therapies for preventing seasonal affective disorder

Forneris, Catherine A; Nußbaumer, Barbara; Kaminski‐Hartenthaler, Angela; Morgan, Laura C; Sonis, Jeffrey; Greenblatt, Amy; Wipplinger, Jörg; Lux, Linda J; Winkler, Dietmar W.; Hofmann, Julia; Noord, Megan Van; Gartlehner, Gerald

doi:10.1002/14651858.cd011270

Cited by 10 publications

(6 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Light therapy, antidepressants or psychotherapy might be appropriate for prevention of SAD. However, with the exception of bupropion XR [49] there is currently a lack of data on preventive strategies for SAD [50–52]. This lack of evidence clearly shows the need for well-conducted, controlled studies on this topic.…”

Section: Discussionmentioning

confidence: 99%

Epidemiology and socioeconomic impact of seasonal affective disorder in Austria

et al. 2016

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Epidemiology and socioeconomic impact of seasonal affective disorder in Austria

et al. 2016

View full text Add to dashboard Cite

show abstract

“…The most commonly used treatments for depression are antidepressants, psychotherapy or a combination of drugs and psychotherapy. While both treatment strategies (alone and in combination) have been shown to be effective,13–15 more recent meta-analyses also found high dropout and low remission rates16–21 as well as clinically significant differences between antidepressant drugs and placebos only for patients at the upper end of the very severely depressed category 22. This may lead patients to search for alternatives.…”

Section: Introductionmentioning

confidence: 99%

Complementary therapies for clinical depression: an overview of systematic reviews

et al. 2019

View full text Add to dashboard Cite

ObjectivesAs clinical practice guidelines vary widely in their search strategies and recommendations of complementary and alternative medicine (CAM) for depression, this overview aimed at systematically summarising the level 1 evidence on CAM for patients with a clinical diagnosis of depression.MethodsPubMed, PsycInfo and Central were searched for meta-analyses of randomised controlled clinical trials (RCTs) until 30 June 2018. Outcomes included depression severity, response, remission, relapse and adverse events. The quality of evidence was assessed according to Grades of Recommendation, Assessment, Development, and Evaluation (GRADE) considering the methodological quality of the RCTs and meta-analyses, inconsistency, indirectness, imprecision of the evidence and the potential risk of publication bias.ResultsThe literature search revealed 26 meta-analyses conducted between 2002 and 2018 on 1–49 RCTs in major, minor and seasonal depression. In patients with mild to moderate major depression, moderate quality evidence suggested the efficacy of St. John’s wort towards placebo and its comparative effectiveness towards standard antidepressants for the treatment for depression severity and response rates, while St. John’s wort caused significant less adverse events. In patients with recurrent major depression, moderate quality evidence showed that mindfulness-based cognitive therapy was superior to standard antidepressant drug treatment for the prevention of depression relapse. Other CAM evidence was considered as having low or very low quality.ConclusionsThe effects of all but two CAM treatments found in studies on clinical depressed patients based on low to very low quality of evidence. The evidence has to be downgraded mostly due to avoidable methodological flaws of both the original RCTs and meta-analyses not following the Consolidated Standards of Reporting Trials and Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Further research is needed.

show abstract

“…There is an evident lack of research on the topic of SAD prevention. Other Cochrane Reviews on SAD prevention but using the interventions of light therapy (Nussbaumer-Streit 2019b) and psychotherapy (Forneris 2019) also included only one study, which was at high risk of bias. However, a Cochrane Review on second-generation antidepressants in preventing SAD yielded more substantial results, demonstrating the effectiveness of bupropion extended release (XL) in preventing SAD but also highlighting a higher risk of harm associated with the medication (Gartlehner 2019).…”

Section: Discussionmentioning

confidence: 99%

Can we prevent seasonal affective disorder (SAD) with melatonergic agents?

Zghoul

2020

BJPsych advances

View full text Add to dashboard Cite

SUMMARYSeasonal affective disorder (SAD) is a recurrent form of major depression, particularly occurring in the winter months with a generally spontaneous remission in spring/summer. The predictable nature of this condition provides a potentially unique opportunity to prevent recurrence in sufferers of SAD. The Cochrane Review discussed here examines the evidence for melatonin and agomelatine in preventing SAD, putting its findings into their clinical context.

show abstract

Psychological therapies for preventing seasonal affective disorder

Abstract: Analysis 1.3. Comparison 1 Mindfulness-based cognitive therapy versus treatment as usual, Outcome 3 Overall discontinuation rate..

Cited by 10 publications

References 29 publications

Epidemiology and socioeconomic impact of seasonal affective disorder in Austria

Epidemiology and socioeconomic impact of seasonal affective disorder in Austria

Complementary therapies for clinical depression: an overview of systematic reviews

Can we prevent seasonal affective disorder (SAD) with melatonergic agents?

Contact Info

Product

Resources

About